Showing results (71-80 of 130) with videos related to
Sort By:
Pageof 13
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 7, 2014
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one yearLuisa Guidi, Manuela Marzo, Gianluca Andrisani, et al.Journal of Clinical Medicine|May 4, 2026
Restorative Surgery in Adult Short Bowel Syndrome: Outcomes from a Single-Center Experience with an Illustrative Complex CaseFederica Galiandro, Carmen Nesci, Giulio Perrone, et al.Journal of Crohn'S & Colitis|April 3, 2012
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agentsAlfredo Papa, Carla Felice, Manuela Marzo, et al.Digestive Diseases (Basel, Switzerland)|April 24, 2008
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspectsAlfredo Papa, Franco Scaldaferri, Silvio Danese, et al.Advances in Therapy|January 27, 2026
Prognostic Significance of Different Endoscopic Scores in Post-Operative Crohn's Disease and their Role in Patients with Low-Risk FeaturesAngelo Del Gaudio, Laura Parisio, Giuseppe Privitera, et al.Therapeutic Advances in Gastroenterology|June 18, 2026
An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patientsAntonio Tursi, Andrea Pasta, Walter Elisei, et al.Journal of Clinical Medicine|January 11, 2024
Cytomegalovirus Infection: An Underrated Target in Inflammatory Bowel Disease TreatmentRossella Maresca, Simone Varca, Federica Di Vincenzo, et al.European Journal of Gastroenterology & Hepatology|March 5, 2026
Impact of biosimilars on the costs of advanced therapies for inflammatory bowel diseases: a population-based study in ItalyAntonio Tursi, Walter Elisei, Annamaria Pia Terlizzi, et al.Inflammatory Bowel Diseases|March 2, 2013
Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remissionAlessandro Armuzzi, Daniela Pugliese, Silvio Danese, et al.Journal of Clinical Medicine|June 13, 2025
Resilience and Self-Care in Patients with Inflammatory Bowel Disease: A Multicentre Cross-Sectional Study in Outpatient SettingsDaniele Napolitano, Mattia Bozzetti, Alessio Lo Cascio, et al.Pageof 13